AMSBIO Launches Animal-Free and Endotoxin-Free Stem Cell Factors
A new range of animal-free and endotoxin-free growth factors and cytokines, tailored to stem cell research, has been launched by AMSBIO — a leading supplier of recombinant proteins.
The success of stem cell research depends on the development of optimal cell culture systems. Both expansion and differentiation of stem cells is highly reliant on growth factor and cytokine supplements, with the activity and purity of these recombinants being critical to successful research and clinical applications. Despite recognised limitations, E. coli and mammalian cells remain the dominant expression systems for commercial recombinant protein production. Although significant improvements in manufacture have been made, both systems present a risk of unwanted contamination from pathogens and endotoxins.
Endotoxins are an unavoidable by-product of commercial E.coli recombinant protein manufacture, including those produced for stem cell research. The stability of endotoxins and affinity for proteins make it almost impossible to completely remove endotoxins. As a result the currently accepted safety limit of endotoxin impurities in recombinant protein products is below < 0.1 ng/µg endotoxin or 1 EU/mg. Although pathogen risks are well documented, there are a growing number of reports that demonstrate endotoxin concentrations as low as 2 pg/mL can result in significant biological responses.
To address the growing body of evidence suggesting accepted levels of endotoxin contamination may significantly compromise stem cell maintenance and differentiation, AMSBIO has launched its new range of animal-free and endotoxin-free growth factors and cytokines. These new recombinant growth factors and cytokines are produced in a plant based expression system that utilises barley seed to eliminate the risks and limitations associated with these traditional expression systems.
Related News
-
News WuXi to sell CGT manufacturing unit to US-based Altaris LLC
At the tail end of 2024, Chinese-based CDMO WuXi AppTec announced the signing of their deal with private equity firm Altaris LLC, confirming the sale of WuXi Advanced Therapies, the cell and gene therapy manufacturing arm of WuXi AppTec. -
News Women in Pharma: Our hopes for 2025 and beyond
Our last instalment for 2024 of the Women in Pharma series brings you messages direct from the Informa Markets CPHI team as they discuss the advice and insights they have carried throughout their roles working at CPHI, and what they hope to see for the... -
News CPHI Milan Wrap-Up Report: Conference Highlights
Discover the emerging and trending topics of the pharmaceutical industry with our CPHI Milan Conference Highlights, with exclusive insight from pharmaceutical leaders and experts! -
News BIOSECURE Act not included in key defense spending bill for 2025
On December 7, 2024, the Biden administration revealed the 2025 National Defense Authorization Act, an annual defense bill specifying the budget and expenditures of the US Department of Defense. The controversial BIOSECURE Act was notably missing from ... -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News Trump 2.0: What does the US election result mean for the healthcare industry?
After Trump won the Presidential election in the US in early November, we take a look at some of the implications a new Trump administration could have on the health and pharmaceutical industry, and on US patients. -
News Women in Pharma: Reflections from Behind the Scenes
In this instalment of our monthly series, the team that brings you the Women in Pharma series each month sits down for a heart-to-heart on what the series means to them, and how they hope to continue their work in the future. -
News Scaling the Industry: CPHI Scale-Up Market interview with YSK Laboratories
For the first time, CPHI Milan hosted the CPHI Start-Up Market, expanding support for emerging and small-sized enterprises in their transition to the next level of growth. In this interview, we spoke with Yuvansh Khokhani, Managing Director of YSK Labo...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance